Laboratory study evaluates in-vitro activity of cefiderocol against MDR and XDR isolates, suggesting therapeutic potential.
PURPOSE: The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-negative bacilli (GNB) poses a major therapeutic challenge. This study evaluated the in-vitro activity of cefiderocol and the synergistic potential of ceftazidime/avibactam with aztreonam against MDR and XDR isolates obtained in a tertiary care hospital from South India. METHODS: A laboratory-based cross-sectional study was conducted with 152 non-duplicate MDR and XDR Gram-negative isolates. Antibiotic susceptibility testing was done by disc diffusion method on Mueller Hinton agar. Carbapenem-resistant isolates were tested for ceftazidime/avibactam-aztreonam synergy using modified E-test/disc diffusion method. Cefiderocol susceptibility was determined in accordance with CLSI 2025 guidelines. Whole genome sequencing (WGS) was performed for cefiderocol-resistant E.coli isolate. RESULTS: Of the 152 isolates, 78 isolates were MDR (38 E.coli, 37 K.pneumoniae, 3 P.aeruginosa) and 74 were XDR (15 E.coli, 32 K.pneumoniae, 15 P.aeruginosa and 12 A.baumannii). Resistance to carbapenems and ceftazidime/avibactam was observed in 82.2% and 65.7% of isolates, respectively. Cefiderocol exhibited the highest in vitro activity, 99.3% of isolates remaining susceptible. Among 115 carbapenem-resistant isolates, all were resistant to aztreonam, while 74.8% showed ceftazidime/avibactam-aztreonam synergy. WGS result of an E.coli isolate showed multidrug-resistance including cefiderocol resistance due to mutations and insertion of 4 amino acids in FtsL protein. CONCLUSIONS: Cefiderocol demonstrated excellent in-vitro activity against MDR and XDR GNB, while the ceftazidime/avibactam-aztreonam combination showed strong synergistic activity among Enterobacterales, highlighting their therapeutic potential. WGS of E.coli isolate confirmed the presence of the genetic determinant associated with cefiderocol resistance gene.
No takes yet. Share an insight, caveat, or question.
Ramakrishnan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: